Alzheimer’s drug prescribed ‘off-label’ for mild cognitive impairment could pose risk for some

March 17, 2017 -

A new study published in the Journal of Alzheimer's Disease shows Donepezil, a medication that is approved to treat people with Alzheimer’s disease, should not be prescribed for people with mild cognitive impairment without a genetic test. UCLA School of Nursing researchers discovered that for people who carry a specific genetic variation — the K-variant of butyrylcholinesterase, or BChE-K — donezpezil could accelerate cognitive decline.


March 17, 2017

Women perform better than men on memory tests for Alzheimer’s

March 8, 2017 - Women do better on verbal memory tests commonly used to diagnose Alzheimer’s disease compared to men with the same amount of neurotoxic protein in their brains, a new study has found. More...

March 8, 2017

Extended Use of MAO-B Inhibitors Slows Decline in Parkinson’s Disease Patients

March 7, 2017 - According to a new report published in the Journal of Parkinson’s Disease More...

March 7, 2017

Vacancy: Marketing Coordinator IOS Press – Neuroscience & Cancer Research Portfolios

April 6, 2017 - We are seeking candidates for our marketing department to fill a position as marketing coordinator for journals and books in the neuroscience and cancer research portfolios. More...

April 6, 2017